TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Dec 24, 2021 09:26 JST
Source:
Eisai
Investigational Alzheimer's Disease Therapy Lecanemab Granted FDA Fast Track Designation
TOKYO, Dec 24, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that lecanemab, an investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early Alzheimer's disease (AD), was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). FDA granted Breakthrough Therapy designation for lecanemab in June of 2021. Breakthrough Therapy designation and Fast Track designation are two FDA programs that are intended to facilitate and expedite development of new drugs to address unmet medical need in the treatment of a serious or life-threatening condition such as AD and provide opportunities for frequent interactions with the FDA.
In September 2021, Eisai initiated a rolling submission to the FDA of a Biologics License application (BLA) for lecanemab under the accelerated approval pathway. The BLA is primarily based on clinical, biomarker and safety data from the Phase 2b clinical study (Study 201) in people with early AD and confirmed amyloid pathology, and non-clinical and clinical parts of the application which consists of three parts (non-clinical, clinical and CMC) have already been submitted. The lecanemab Phase 2b study results demonstrated a high degree of Aβ plaque lowering and consistent reduction of clinical decline across several clinical endpoints. The correlation between the extent of Abeta plaque reduction and effect on clinical endpoints in Study 201 further supports Abeta as a surrogate endpoint that is reasonably likely to predict clinical benefit.
The lecanemab Clarity AD Phase 3 clinical study in early AD is ongoing and completed enrollment in March 2021 with 1,795 patients. The FDA has agreed that the results of Clarity AD, when completed, can serve as the confirmatory study to verify the clinical benefit of lecanemab. Blinded safety data from Clarity AD is included to support the ongoing rolling submission. Another Phase 3 clinical study, AHEAD 3-45, is evaluating the efficacy of treatment with lecanemab in participants with preclinical AD and elevated amyloid and in participants with early preclinical AD and intermediate amyloid. Additionally, Eisai has initiated a lecanemab subcutaneous dosing Phase 1 study.
Alzheimer's Disease is a serious, progressive and devastating disease with few treatment options. Eisai and Biogen are committed to bring new treatment options to people living with early AD, their families and healthcare professionals who are waiting for them as early as possible.
Source: Eisai
Sectors: BioTech
Copyright ©2022 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
May 27 2022 11:49 JST
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS
May 27 2022 11:24 JST
Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer's Disease Under the Accelerated Approval Pathway
May 10 2022 10:23 JST
Eisai Initiates Preparation for New Drug Application, Based on the Results of an Investigator-Initiated Clinical Trial of Ultrahigh-Dose Mecobalamin for Amyotrophic Lateral Sclerosis in Japan
May 10 2022 10:00 JST
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business
April 01 2022 13:05 JST
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor
March 28 2022 21:38 JST
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting
March 22 2022 09:21 JST
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen
March 15 2022 12:03 JST
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments
March 15 2022 11:00 JST
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting
March 11 2022 11:15 JST
More Press release >>
Latest Press Release
Toyota Announces Adjustments to Domestic Production in June
May 27, 2022 17:54 JST
TOYOTA GAZOO Racing Targets Gravel Double in Sardinia
May 27, 2022 17:27 JST
Eisai Contributes to the Science of Cancer Medicine at ASCO 2022
May 27, 2022 12:49 JST
Eisai: MHLW Grants Orphan Drug Designation in Japan to Mecobalamin Ultrahigh-Dose Formulation with Prospective Indication for Delaying the Progression of Disease and Functional Impairment of ALS
May 27, 2022 12:24 JST
The Ajinomoto Foundation, Sysmex, and NEC initiate a cross-industry co-creation project to improve maternal and child health and nutrition in the Republic of Ghana
May 27, 2022 09:52 JST
NEC and Juniper Networks Deploy Algeria Telecom's Nationwide 5G-Ready IP Metro Network
May 25, 2022 17:50 JST
Hitachi and Hitachi Astemo Developed Thin-type Inverter Technology for EVs That is More Compact and Energy Efficient
May 25, 2022 11:02 JST
DENSO, Honeywell Co-Develop E-Motor for Lilium's All-Electric Jet
May 25, 2022 10:01 JST
Toyota Announces May/June Production Suspension and June Production Plan
May 24, 2022 13:53 JST
NEC Provides AI-based Traffic Monitoring System with Fiber-optic Sensing Technology for NEXCO CENTRAL
May 24, 2022 11:27 JST
Mitsubishi Corporation signs Participation Agreement with Sempra Infrastructure, TotalEnergies, Mitsui for Carbon Sequestration Project in Louisiana
May 24, 2022 10:10 JST
Hitachi launches Lumada Inspection Insights and strengthens digital and green portfolio
May 24, 2022 09:16 JST
Project-Finance Agreement Signed for MC-Hokuden Hydro Power Alliance
May 23, 2022 11:15 JST
Mitsubishi Motors to Launch the All-New eK X EV in Japan
May 23, 2022 09:36 JST
NEC and Toyota Technical Development Develop Stable Wireless Control System for Cars and other Moving Objects in Factories
May 23, 2022 09:24 JST
MC and Morgenrot Enter into Capital and Business Alliance
May 20, 2022 20:19 JST
ROOKIE Racing and TOM'S SPIRIT Announce Team Setups for Super Taikyu Series Fuji 24 Hours Race
May 20, 2022 13:42 JST
MC and Kurashiki City Sign Regional Development Agreement
May 20, 2022 10:55 JST
BDO announces winners of the BDO ESG Awards 2022
May 19, 2022 22:20 JST
MHI-MS Introduces the New "MC" Flexo Folder Gluer: The Latest Innovation from the World's Leading Industrial Firm
May 18, 2022 20:36 JST
More Latest Release >>